



PATENT Docket No. 282172002800

#### CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in a box addressed to: Mail Stop Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on July 21, 2004.

Andy Gi

Sandy Yi

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Thomas W. DUBENSKY, Jr. et al.

Serial No.: 10/773,618

Filing Date: February 6, 2004

For: MODIFIED FREE-LIVING MICROBES,

VACCINE COMPOSITIONS AND METHODS OF USE THEREOF

Examiner: Not Yet Assigned

Group Art Unit: 1645

# INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. § 1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references are not submitted. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record in the application.

	This I	nformation Disclosure Statement is submitted:
	With	the application; accordingly, no fee or separate requirements are required.
	Before	e the mailing of a first Office Action after the filing of a Request for Continued
	Exam	ination under § 1.114. However, if applicable, a certification under 37 C.F.R. §
	1.97(€	e)(1) has been provided.
$\boxtimes$	Withi	n three months of the application filing date or before mailing of a first Office
	Action	on the merits; accordingly, no fee or separate requirements are required.
	Howe	ver, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
	After	receipt of a first Office Action on the merits but before mailing of a final Office
	Action	n or Notice of Allowance.
		A fee is required. A check in the amount of is enclosed.
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached
		to this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee
		is believed to be due.
	After	mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue	fee.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the
		amount of is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal
		form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 282172002800. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: July 21, 2004

Respectfully submitted,

Alicia J. Hager

Registration No. 44,140

Morrison & Foerster LLP

755 Page Mill Road

Palo Alto, California 94304-1018

Telephone: (650) 813-4296 Facsimile: (650) 494-0792

der the Paperwork Reduction Act of 1995, no persons are required to res

PTO/SB/21 (02-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE nd to a collection of information unless it displays a valid OMB control number.

# **TRANSMITTAL FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

portu to a collection or internation	Turness it displays a valid Offic Condornation
Application Number	10/773,618
Filing Date	February 6, 2004
First Named Inventor	Thomas W. DUBENSKY, Jr.
Art Unit	1645
Examiner Name	Not Yet Assigned
Attorney Docket Number	282172002800

ENCLOSURES (Check all that apply)					
Fee Transr	nittal Form	Drawing(s)	After Allowance communication to Technology Center (TC)		
Fee /	Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences		
Amendmer	nt/Reply	Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
After	Final	Petition to Convert to a Provisional Application	Proprietary Information		
Affida	avits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter		
Extension of	of Time Request	Terminal Disclaimer	X Other Enclosure(s) (please Identify below):		
Express At	pandonment Request	Request for Refund	<ol> <li>Form PTO-1449 + copy (24 pages)</li> </ol>		
	Disclosure Statement pages)	CD, Number of CD(s)	<ul><li>2. 159 References</li><li>3. Return Postcard</li></ul>		
	opy of Priority				
	s) to Missing Parts/ Application	Remarks			
	onse to Missing Parts				
	r 37 CFR 1.52 or 1.53				
_	SIGNATI	JRE OF APPLICANT, ATTORNEY, OF	RAGENT		
Firm or Individual name	MORRISON & FOERSTER LLP (Customer No. 25226) Alicia J. Hager - 44,140				
Signature	M	11. The			
Date	July 21, 2004				

28 +

159 Refs.

				Postal Service with sufficient postage as Box 1450, Alexandria, VA 22313-1450	
D-4-4-1-4-04-0004	0:	1.	1 11:	(01-)(0)	•

Dated: July 21, 2004

JUL 2 6 2004

Form PTC 1449

# INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

	5.1001 1 01 12
Docket Number 282172002800	Application Number 10/773,618
Applicant	
Thomas W.	DUBENSKY, Jr. et al.
Filing Date February 6, 2004	Group Art Unit 1645

## **U.S. PATENT DOCUMENTS**

Mailing Date July 21, 2004

Examiner Initials	Ref. No.	Date	Document No.	Name ·	Class	Subclass	Filing Date If Appropriate
	1.	02/28/2002	2002/0025323	Paterson et al.			
	2.	03/07/2002	2002/0028206	Paterson			
<u> </u>	3.	04/18/2002	2002/0045587	Goebel			
	4.	10/17/2002	2002/0150588	Allison et al.			
	5.	05/01/2003	2003/0082510	Wollowitz et al.			
	6.	06/19/2003	2003/0113704	Stassinopoulos et al.			
	7.	10/30/2003	2003/0202985	Paterson			
<u> </u>	8.	10/30/2003	2003/0203472	Portnoy et al.			
	9.	01/22/2004	2004/0013690	Portnoy et al.			
•	10.	02/12/2004	2004/0029897	Cook et al.			
	11.	12/15/1992	5,171,568	Burke et al.			
	12.	01/19/1993	5,180,819	Cayre			
	13.	03/21/1995	5,399,719	Wollowitz et al.			
	14.	01/14/1997	5,593,823	Wollowitz et al.		-	
	15.	11/25/1997	5,691,132	Wollowitz et al.			
	16.	11/03/1998	5,830,702	Portnoy et al.			
	17.	12/01/1998	5,843,459	Wang et al.			
	18.	03/02/1999	5,877,159	Powell et al.			
	19.	12/21/1999	6,004,815	Portnoy et al.			
	20.	04/18/2000	6,051,237	Paterson			
	21.	07/25/2000	6,093,725	Cook et al.			
	22.	08/08/2000	6,099,848	Frankel et al.			
	23.	10/17/2000	6,133,460	Wollowitz et al.			
	24	11/07/2000	6,143,490	Cook et al.			
	25.	11/07/2000	6,143,551	Goebel			
	26.	11/21/2000	6,150,170	Powell et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

#### Docket Number 282172002800 Application Number 10/773,618 Form PTO-1449 INFORMATION DISCLOSURE CITATION Applicant Thomas W. DUBENSKY, Jr. et al. IN AN APPLICATION Filing Date February 6, 2004 Group Art Unit 1645 (Use several sheets if necessary) Mailing Date July 21, 2004 27. 11/28/2000 6,153,430 Pastan et al. 28. 08/07/2001 6,270,952 Cook et al. 29. 6,287,556 Portnoy et al. 09/11/2001 6,455,286 Wollowitz et al. 30. 09/24/2002 Cook et al. 31. 02/04/2003 6,514,987 32. Paterson 05/20/2003 6,565,852 08/12/2003 6,605,286 Steidler et al. 33. FOREIGN PATENT DOCUMENTS Subclass Translation Ref. Document No. Country Class Examiner Date YES NO **Initials** No. WO 89/04669 34. 06/01/1989 **WIPO** 10/04/1990 WO 90/11089 **WIPO** 35. **WIPO** 36. 11/29/1990 WO 90/14436 37. 08/05/1993 WO 93/15212 **WIPO** Abstract 38. 05/17/1996 WO 96/14087 **WIPO WIPO** 39. 01/22/1998 WO 98/02523 40. 07/16/1998 WO 98/30545 **WIPO** 07/23/1998 WO 98/31786 **WIPO** 41. 42. 05/27/1999 WO 99/25376 **WIPO** 06/03/1999 WO 99/26476 **WIPO** 43. **WIPO** 44. 07/08/1999 WO 99/34007 **WIPO** 45. 09/23/1999 WO 99/47646 46. 02/08/2001 WO 01/08701 **WIPO** WO 01/24637 **WIPO** 47. 04/12/2001 48. 04/19/2001 WO 01/27295 **WIPO** Abstract WO 01/72329 **WIPO** 49. 10/04/2001 **WIPO** 50. 06/27/2002 WO 02/50262 51. 08/15/2002 WO 02/062298 **WIPO** DATE CONSIDERED: **EXAMINER:**

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92) pa- 871914 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449				Docket Number 282172002800 Application Number 10/773,		mber 10/773,61	18		
INFOR	MATI	ON DISCLO	SURE CITATION		Applicant				
	IN	AN APPLIC	ATION		Thomas W. DUBENSKY, Jr. et al.				
	(U	se several sheets if i	necessary)		Filing Date February 6, 20	04	Group Art Unit	1645	
					Mailing Date July 21, 200	)4			
	52.	10/03/2002	WO 02/077249	WI	РО				
	53.	12/05/2002	WO 02/097044	WI	PO				
	54.	07/31/2003	WO 03/061379	WI	PO				
-	55.	11/13/2003	WO 03/092600	WI	PO				
	56.	12/11/2003	WO 03/102168	WI	PO				
	57.	01/22/2004	WO 2004/006837	WI	PO				
•									
-		. (	OTHER DOCUME	NTS	(including author, title, D	ate, Pertinent F	ages, Etc.)		
Examiner	Ref.	Title							
Initials	No.				1 99451				
	58. Aggarwal, A. et al. (October, 1990). "Oral <i>Salmonella</i> : Malaria Circumsporozoite Recombinants Induce Specific CD8 <sup>+</sup> Cytotoxic T Cells," <i>J. Exp. Med.</i> 172:1083-1090.			nts					
• • •	59. Angelakopolous, H. et al. (July, 2002). "Safety and Shedding of an Attenuated Strain of Listeria								
		monocytogenes with a Deletion of actA/plcB in Adult Volunteers: A Dose Escalation Study of Oral Inoculation," Infection and Immunity 70(7):3592-3601.							
	60.	Anthoney, D 1(1):67-81.	A. et al. (2001). "Dî	VA: S	Still A Target Worth	Aiming At	?" Am. J. Pha	rmacogeno	omics
	61.	Appelberg, F	R. et al. (February, 20 Cell-to-Cell Spreadi						
			tion and Immunity 68			crate in rie	patocytes of f		
	62.		et al. (1999). "Conser ucleic Acids Research			pair Proteir	ns and Evolut	ion of Repa	ir
	63.	1 0 /	al. (December, 2001	,		1		-	
		1	omas of the Pancreas Gene Expression (SA					rker by Ser	ıal 
	64.		. et al. (September, 2 Listeria monocytoge						
			d Immunity 69(9):595						
	65.		l. (July, 1984). "DNA ature 310:207-211.	Seq	uence and Expression	on of the B	95-8 Epstein-	Barr Virus	
	66.		A. et al. (January, 200 n," <i>Infection and Imm</i>			egnant Guir	nea Pig: A Mo	odel of Ver	tical
•	67. Ballard, J.D. et al. (1996). "Anthrax Toxin-Mediated Delivery of a Cytotoxic T-Cell Epitope in viv Proc. Natl. Acad. Sci. USA 93:12531-12534.				n vivo,"				
EXAMI	NER:				DATE CONSI	DERED:			
	EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.								

PTO/SB/ 08 (2-92) pa- 871914 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO	-1449		Docket Number 282172002800	Application Number 10/773,618	
INFOR		ON DISCLOSURE CITATION AN APPLICATION	Applicant Thomas W. DUBENSKY, Jr. et al.		
		se several sheets if necessary)	Filing Date February 6, 2004	Group Art Unit 1645	
		·	Mailing Date July 21, 2004		
			1		
	68.	Bierne, H. et al. (September, 2002). "It as an Invasin and a Growth Factor," Ja			
	69.	Bishop, D.K. et al. (September 15, 198 monocytogenes: The Influence of In V Immunol. 139(6):2005-2009.			
	70.	Biswas, I. et al. (June, 1993). "High-Endergo Bacteria," J. Bacteriol. 175(1		Replacement System for Gram-	
	71.	Bouwer, H.G.A. et al. (May 6, 2003). of Anti-Tumor Responses," Poster, pre Anniversary Meeting, Denver, CO (Ma	esented at The American Associa		
	72.	Boyaka, P.N. et al. (1999). "IL-12 Is at Journal of Immunology 162:122-128.	n Effective Adjuvant for Inducti	on of Mucosal Immunity," The	
	73.	Boyaka, P.N. et al. (June, 2003). "Effe and Th Cell Responses Following Nas <i>Immunology</i> 170:5636-5643.			
	74.		. "Novel Genes in the PAGE and GAGE Family of Tumor ting in the dbEST Database," Cancer Research 59:1445-1448.		
Striking Antigen-Specific CD8+ T-C			003). "Recombinant Attenuated Listeria Monocytogenes Elicits Cell Responses that Correlate with Prolonged Survival in a oma," presented at Keystone Symposia Meeting, Keystone, CO		
	76.		). "Recombinant Attenuated Listeria monocytogenes Elicits Tumor-Associated Antigen in Listeria Immune Mice," Abstract cular Symposium website, one page.		
·	77.	Brockstedt, D. et al. (October 3, 2003) Strains for Cancer Immunotherapy Ap (October 1 -3, 2003), one page.			
	78.	Brook, I. et al. (2001). "Susceptibility Intratracheal Route of Infection," J. M.		nthracis Sterne by the	
	79.	Brossier, F. et al. (April, 2000). "Role Infection and Immunity 68(4):1781-17	ole of Toxin Functional Domains in Anthrax Pathogenesis," -1786.		
80. Brossier, F. et al. (October, 2000). "Pro Heterologous Protein Produced In Vive 5734.					
	81.	Brown, E.R. et al. (1955). "Specific Id Bacteriophage," J. Infect. Dis. 96:34-3		s by Means of a Variant	
EXAMIN	JER:	- Control of the Cont	DATE CONSIDERED:		
		al to structure and all the structure and the st	C	iiahah.ah.aaiaaiai.Gai	
	EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.				

Form PTO-1449		Docket Number 282172002800	Application Number 10/773,618	
1	ON DISCLOSURE CITATION AN APPLICATION	Applicant  Thomas W. DUBENSKY, Jr. et al.		
	lse several sheets if necessary)	Filing Date February 6, 2004	Group Art Unit 1645	
		Mailing Date July 21, 2004		
	1			
82.	Camilli, A. et al. (1993). "Dual Roles <i>Microbiology</i> 8(1):143-157.	of plcA in Listeria monocytoger	nes Pathogenesis," Molecular	
83.	Campbell, P.A. (1994). "Macrophage- Interactions Marcel Dekker, Inc. 60:3		9 In Macrophage Pathogen	
84.	Carles-Kinch, K. et al. (May 15, 2002) Malignant Cell Behavior," Cancer Res		phA2 Tyrosine Kinase Inhibits	
85.	Chee, M.S. et al. (1990). "Analysis of Cytomegalovirus Strain AD169" <i>In</i> C 125-169.			
86.	Cheo, D.L. et al. (September, 1993). "Induction and Competence Induction 175(18):5907-5915.			
87.	Cossart, P. et al. (1998). "Interactions Entry and Actin-Based Movement: Ba Journal 17(14):3797-3806.			
88.	Cossart, P. et al. (2001). "The Use of I monocytogenes," Current Opinion in	of Host Cell Machinery in the Pathogenesis of Listeria in Immunology 13:96-103.		
89.	Cossart, P. et al. (January, 2003). "Inv Functional Mimicry to Subvert Cellula			
90.	Da Ros, T. et al. (2001). "DNA-Photo 1821.	cleavage Agents," Current Pha	rmaceutical Design 7:1781-	
91.	Davison, A.J. et al. (1986). "The Com 67:1759-1816.	omplete DNA Sequence of Varicella-Zoster Virus," J. Gen. Virol.  000). "A PEST-Like Sequence in Listeriolysin O Essential for ity," Science 290:992-995.		
92.	Decatur, A.L. et al. (November 3, 200 Listeria monocytogenes Pathogenicity			
93.	Gene in Listeria monocytogenes Who	Identification and Characterization of a Novel PrfA-Regulated nose Product, IrpA, Is Highly Homologous to Internalin Proteins, ats," <i>Infection and Immunity</i> 65(1):101-109.		
94.		Listeria monoctyogenes Into Hepatocytes Requires Expression of nalin Multigene Family," Molecular Microbiology 16(2):251-261.		
95.	Dramsi, S. et al. (May, 1997). "Identif Family of <i>Listeria monocytogenes</i> EG			
96.	Dubensky, T. (February 22, 2003). "C Listeria Monocytogenes," <i>Presented a</i> 2003) 22 pages.			
			(	
EXAMINER:		DATE CONSIDERED:		
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not i conformance and not considered. Include a copy of this form with next communication to applicant.				

Form PTO-1449	)	Docket Number 282172002800	Application Number 10/773,618	
_	TION DISCLOSURE CITATION N AN APPLICATION	Applicant  Thomas W. DUBENSKY, Jr. et al.		
	(Use several sheets if necessary)	Filing Date February 6, 2004	Group Art Unit 1645	
		Mailing Date July 21, 2004		
97.		ncer Vaccines Derived From Selected Attenuated Strains of at Days of Molecular Medicine - Immunotherapy, 24 pages.		
98.	Dubensky, T. (December 4, 2003). "Li Cancer: Vaccines Disguised as an Invapages.	steria-Based Therapeutic Vaccinding Pathogen," presented at Jo	nes for Infectious Disease and hns Hopkins University, 57	
99.	Esin, S. et al. (1996). "Proliferation of Soluble Extracts of <i>Mycobacterium tud</i> 425.			
. 100.	Fong, L. et al. (July 17, 2001). "Altere Dendritic Cells for Tumor Immunothe			
. 101.	Foon, K.A. et al. (November, 1995). "with an Anti-Idiotype Antibody Mimid 1:1285-1294.			
102.	Gaillard, JL. et al. (June 28, 1991). "Internalin, a Repeat Protein Reminisce 65:1127-1141.			
103.	103. Gedde, M.M. et al. (February, 2000). "Role of Listeriolysin O in Cell-To-Cell Spread of Listeria monocytogenes," Infection and Immunity 68(2):999-1003.			
104.	Gentschev, I. et al. (February, 2002). " Intracellular Bacteria," Int. J. Med. Mi		d DNA by Attenuated	
105.	Giedlin, M. et al. (March 9, 2004). "The on Psoralen-Killed Metabolically Action Society for Microbiology Biodefense Research	ve DNA Repair Mutants," Poste	r, presented at American	
106.	Glaser, P. et al. (October 26, 2001). "C 852.	"Comparative Genomics of Listeria Species," Science 294:849-		
107.	Glomski, I.J. et al. (March 18, 2002). Optimum to Compartmentalize Activity <i>Biology</i> 156(6):1029-1038.	"The Listeria monocytogenes H ty and Prevent Damage to Infect	emolysin Has an Acidic pH ed Host Cells," <i>Journal of Cell</i>	
108.	Green, B.D. et al. (August, 1985). "De Infection and Immunity 49(2):291-297	Demonstration of a Capsule Plasmid in Bacillus anthracis,"  97.		
109.	Gregory, S.H. et al. (October, 1996). " Not Required for Entry into Hepatic C			
110.	Gregory, S.H. et al. (December, 1997) monocytogenes in Mouse Hepatocytes			
EXAMINER:		DATE CONSIDERED:		
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.				

Form PTO-1449			Docket Number 282172002800	Application Number 10/773,618	
INFORMA		ON DISCLOSURE CITATION	Applicant Thomas W. DUBENSKY, Jr. et al.		
		AN APPLICATION		<del></del>	
	(Us	e several sheets if necessary)	Filing Date February 6, 2004	Group Art Unit 1645	
			Mailing Date July 21, 2004		
		1 (2001) HT		771 - F D:00	
11	1.	Gunn, G.R. et al. (2001). "Two Listeria Molecular Forms of Human Papilloma Immunity That Correlates with Their A Immortalized by HPV-16," The Journal	Nirus-16 (HPV-16) E7 Induce Ability to Induce Regression of I	Qualitatively Different T Cell Established Tumors	
11	2.	Hammarström, S. (1999). "The Carcin Functions and Expression in Normal a			
11	3.	Harm, W. (1979). "Relative Effectiven Production of Primary Lethal Damage			
. 11	4.	Hei, D.J. et al. (March, 1999). "Elimin Aliquots by Photochemical Treatment 248.	ation of Cytokine Production in with Psoralen Plus Ultraviolet A	Stored Platelet Concentrate A Light," <i>Transfusion</i> 39:239-	
· 11	5.	Hess, J. et al. (May, 1995). "Listeria m Survival of Attenuated Salmonella typ	nonocytogenes p60 Supports Ho himurium," Infection and Immu	st Cell Invasion by and In Vivo nity 63(5):2047-2053.	
11	6.		ular Biology of the Hepatitis C Viruses: Implications For I of Viral Disease," <i>Hepatology</i> 14(2):381-388.		
11	7.	Huang, E.H. et al. (June, 2002). "CEA	A-Based Vaccines," Exper. Rev. Vaccines 1(1):49-63.		
11	8.		e Listeria monocytogenes Protein In1B Is an Agonist of ase," The Journal of Biological Chemistry 274(24):17025-17032.		
11	9.	Jung, S. et al. (August, 2002). "In Vivo CD8 <sup>+</sup> T Cells by Exogenous Cell-Asso	o Depletion of CD11c <sup>+</sup> Dendrition Deciated Antigens," <i>Immunity</i> 17:	c Cells Abrogates Priming of 211-220.	
12	20.		lentification of a Human Melanoma Antigen Recognized by sociated with in vivo Tumor Rejection," Proc. Natl. Acad. Sci.		
12	21.	Kawashima, H. et al. (1984). "Function the Mutational Sites in the Gene," Mo	onal Domains of Escherichia coli recA Protein Deduced From tol. Gen. Genet. 193:288-292.		
12	22.	Keogh, E. et al. (2001). "Identification Antigens: Recognition of Naturally Praffinity," <i>The Journal of Immunology</i>	on of New Epitopes From Four Different Tumor-Associated Processed Epitopes Correlates with HLA-A*0201-Binding gy 167:787-796.		
12	23.	Ko, M. et al. (July, 2002). "Group I Se <i>Bacteriol</i> . 184(14):3917-3922.	elf-Splicing Intron in the recA G	ene of Bacillus anthracis," J.	
12	24.	Kocks, C. et al. (February 7, 1992). "L Gene Product, a Surface Protein," Cell	monocytogenes-Induced Actir 1 68:521-531.	Assembly Requires the actA	
12	25.	Kolb-Mäurer, A. et al. (June, 2000). "In Uptake and Host Cell Response," Infe	Listeria monocytogenes-Infected ction and Immunity 68(6):3680-	l Human Dendritic Cells: 3688.	
EXAMINER	₹:		DATE CONSIDERED:		
		al if citation considered, whether or not the citation considered. Include a copy of this form with r		line through the citation if not in	

Form PTO-1449		Docket Number 282172002800	Application Number 10/773,618	
	ON DISCLOSURE CITATION AN APPLICATION	Applicant Thomas W. DUBENSKY, Jr. et al.		
	ise several sheets if necessary)	Filing Date February 6, 2004	Group Art Unit 1645	
·		Mailing Date July 21, 2004		
_		L		
126.	Lage, C. et al. (November, 2003). "Ne DNA Adducts Induced by Chemothera Escherichia coli cells," Mutation Rese	apeutic Agents and Psoralens Plu		
127.	Lauer, P. et al. (August, 2002). "Const monocytogenes Site-Specific Phage In 4186.			
128.	Lauvau, G. et al. (November 23, 2001) Killed Bacterial Vaccine," Science 294		Effector CD8 T Cells by a	
129.	Lenz, L.L. et al. (October 14, 2003). "S Listeria monocytogenes Pathogenesis,"	SecA2-Dependent Secretion of A Proc. Natl. Acad. Sci. USA 100	Autolytic Enzymes Promotes 0(21):12432-12437.	
. 130.	Leong, M. et al. (February 3, 2004). "Functional Immune Response Specific Cellular and Humoral Immunity," <i>Gor Immunobiology Conference</i> (February	c to a Heterologous Antigen in the don Research Conference on Im	he Presence of Listeria-Specific munochemistry &	
131.		Tumor Immunity Within the Central Nervous System Stimulated tenes Vaccination," Cancer Research 62:2287-2293.		
132.	Lillard, J.W. et al. (2001). "RANTES I Journal of Immunology 166:162-169.		cosal Immune Response," The	
133.	Lim, S.H. et al. (March 1, 2001). "Spendyeloma," <i>Blood</i> 97(5):1508-1510.	rm Protein 17 is a Novel Cancer	-Testis Antigen in Multiple	
134.	Lin, L. (January/February, 1998). "Pso Medicine pp. 54-63.	oralen Photochemical Treatment	of Platelets," Science and	
135.	Little, S.F. et al. (December, 1997). "Panthracis Infection in Guinea Pigs," In			
136.	, , , , , , , , , , , , , , , , , , , ,	1). "Internalin B Activates Nuclear Factor-kB via Ras,  The Journal of Biological Chemistry 276(47):43597-43603.		
137.		Proteolytic Pathways of Activation and Degradation of a tracellular Infection by Listeria monocytogenes, "J. Cell Biol.		
138.	Mayordomo, J.I. et al. (December, 199 Synthetic Tumour Peptides Elicit Proto 1(12):1297-1302.	995). "Bone Marrow-Derived Dendritic Cells Pulsed With otective and Therapeutic Antitumour Immunity," <i>Nat. Med.</i>		
139.	McGeoch, D.J. et al. (1988). "The Cor Genome of Herpes Simplex Virus Typ			
140.	Mikesell, P. et al. (January, 1983). "Evanthracis," Infection and Immunity 39		oxin Production in Bacillus	
EXAMINER:		DATE CONSIDERED:		
	ial if citation considered, whether or not the citation considered. Include a copy of this form with n		line through the citation if not in	

Form PTO-1449		Docket Number 282172002800	Application Number 10/773,618
INFORMATION DISCLOSURE CITATION		Applicant	
IN AN APPLICATION		Thomas W. DUBENSKY, Jr. et al.	
(Use several sheets if necessary)		Filing Date February 6, 2004	Group Art Unit 1645
		Mailing Date July 21, 2004	
141.	Mitsuyama, M. et al. (May, 1990). "Difference in the Induction of Macrophage Interleukin-1 Production between Viable and Killed Cells of <i>Listeria monocytogenes</i> ," <i>Infection and Immunity</i> 58(5):1254-1260.		
142.	Mock, M. et al. (2001). "Anthrax," Ann. Rev. Microbiol. 55:647-671.		
143.	Molldrem J. et al. (October 1, 1996). "Targeted T-cell Therapy for Human Leukemia: Cytotoxic T Lymphocytes Specific for a Peptide Derived from Proteinase 3 Preferentially Lyse Human Myeloid Leukemia Cells," <i>Blood</i> 88(7):2450-2457.		
144.	Molldrem, J.J. et al. (October 1, 1997). "Cytotoxic T Lymphocytes Specific for a Nonpolymorphic Proteinase 3 Peptide Preferentially Inhibit Chronic Myeloid Leukemia Colony-Forming Units," <i>Blood</i> 90(7):2529-2534.		
. 145.	Molldrem, J.J. et al. (June 1, 1999). "A PR1-Human Leukocyte Antigen-A2 Tetramer Can Be Used to Isolate Low-Frequency Cytotoxic T Lymphocytes From Healthy Donors That Selectively Lyse Chronic Myelogenous Leukemia," <i>Cancer Research</i> 59:2675-2681.		
146.	Molldrem, J.J. et al. (September, 2000). "Evidence That Specific T Lymphocytes May Participate in the Elimination of Chronic Myelogenous Leukemia," <i>Nature Medicine</i> 6(8):1018-1023.		
147.	Molldrem, J.J. et al. (December, 2002). "The Basis of T-Cell-Mediated Immunity to Chronic Myelogenous Leukemia," <i>Oncogene</i> 21:8668-8673.		
148.	Moors, M.A. et al. (January, 1999). "Expression of Listeriolysin O and ActA by Intracellular and Extracellular Listeria monocytogenes," Infection and Immunity 67(1):131-139.		
149.	Morgan, D.J. et al. (1998). "Activation of Low Avidity CTL Specific for a Self Epitope Results in Tumor Rejection But Not Autoimmunity," J. Immunol. 160:643-651.		
150.	Morse, M.A. et al. (June, 1999). "A Phase I Study of Active Immunotherapy with Carcinoembryonic Antigen Peptide (CAP-1)-pulsed, Autologous Human Cultured Dendritic Cells in Patients with Metastatic Malignancies Expressing Carcinoembryonic Antigen," Clin. Cancer Res. 5:1331-1338.		
151.	Muller-Berat, N. et al. (January, 1994). "The Phylogeny of Proteinase 3/Myeloblastin, The Autoantigen in Wegener's Granulomatosis, and Myeloperoxidase as Shown by Immunohistochemical Studies on Human Leukemic Cell Lines," Clin. Immunol. Immunopath. 70(1):51-59.		
152.	Nicolaou, K.C. et al. (July, 1993). "Chemistry and Biology of Natural and Designed Enediynes," Proc. Natl. Acad. Sci. USA 90:5881-5888.		
153.	Nishiyama, T. et al. (January, 2001). "Immunotherapy of Bladder Cancer Using Autologous Dendritic Cells Pulsed with Human Lymphocyte Antigen-A24-Specific MAGE-3 Peptide," <i>Clinical Cancer Research</i> 7:23-31.		
154.	O'Riordan, M. et al. (October 17, 2003). "Listeria Intracellular Growth and Virulence Require Host- Derived Lipoic Acid," Science 302:462-464.		
155.	Pace, J.L. et al. (1998). "Inactivated Whole-Cell Bacterial Vaccines: Current Status and Novel Strategies," <i>Vaccine</i> 16(16):1563-1574.		
EXAMINER:		DATE CONSIDERED:	·
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449		Docket Number 282172002800	Application Number 10/773,618
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Thomas W. DUBENSKY, Jr. et al.	
l		Filing Date February 6, 2004	Group Art Unit 1645
		Mailing Date July 21, 2004	
156.	Palucka, K. et al. (August, 1999). "Linking Innate and Adaptive Immunity," <i>Nature Medicine</i> 5(8):868-870.		
157.	Pan, Z-K. et al. (October 15, 1999). "Regression of Established B16F10 Melanoma with a Recombinant Listeria monocytogenes Vaccine," Cancer Research 59:5264-5269.		
158.	Portnoy, D.A. et al. (August 5, 2002). "The Cell Biology of <i>Listeria monocytogenes</i> Infection: The Intersection of Bacterial Pathogenesis and Cell-Mediated Immunity," <i>The Journal of Cell Biology</i> 158(3):409-414.		
159.	Price, B. M. et al. (July, 2001). "Protection Against Anthrax Lethal Toxin Challenge by Genetic Immunization with a Plasmid Encoding the Lethal Factor Protein," <i>Infection and Immunity</i> 69(7):4509-4515.		
. 160.	Raffelsbauer, D. et al. (1988). "The Gene Cluster inlC2DE of Listeria monocytogenes Contains Additional New Internalin Genes and Is Important for Virulence in Mice," Mol. Gen. Genet. 260:144-158.		
161.	Read, T.D. et al. (June 14, 2002). "Comparative Genome Sequencing For Discovery of Novel Polymorphisms in <i>Bacillus anthracis</i> ," <i>Science</i> 296:2028-2033.		
162.	Renkvist, N. et al. (2001). "A Listing of Human Tumor Antigens Recognized by T Cells," <i>Cancer Immunol. Innumother.</i> 50:3-15.		
163.	Rhie, G-E. et al. (September 16, 2003). "A Dually Active Anthrax Vaccine That Confers Protection Against Both Bacilli and Toxins," <i>Proc. Natl. Acad. Sci. USA</i> 100(19):10925-10930.		
164.	Rolph, M.S. et al. (2001). "CD40 Signaling Converts a Minimally Immunogenic Antigen into a Potent Vaccine Against the Intracellular Pathogen Listeria monocytogenes," The Journal of Immunology 166:5115-5121.		
165.	Salazar, E. et al. (2000). "Agonist Peptide From a Cytotoxic T-Lymphocyte Epitope of Human Carcinoembryonic Antigen Stimulates Production of TC1-Type Cytokines and Increases Tyrosine Phosphorylation More Efficiently Than Cognate Peptide," <i>Int. J. Cancer</i> 85:829-838.		
166.	Sancar, A. et al. (1988). "DNA Repair Enzymes," Ann. Rev. Biochem. 57:29-67.		
167.	Schafer, R. et al. (July 1, 1992). "Induction of a Cellular Immune Response to a Foreign Antigen by a Recombinant Listeria monocytogenes Vaccine," <i>The Journal of Immunology</i> 149:53-59.		
168.	Sheehan, B. et al. (November, 1995). "Differential Activation of Virulence Gene Expression by PrfA, the Listeria monocytogenes Virulence Regulator," Journal of Bacteriology 177(22):6469-6476.		
169.	Shen, H. et al. (April, 1995). "Recombinant Listeria monocytogenes as a Live Vaccine Vehicle for the Induction of Protective Anti-Viral Cell-Mediated Immunity," Proc. Natl. Acad. Sci. USA 92:3987-3991.		
170.	Shen, H. et al. (February 20, 1998). "Compartmentalization of Bacterial Antigens: Differential Effects on Priming of CD8 T Cells and Protective Immunity," <i>Cell</i> 92:535-545.		
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449		Docket Number 282172002800	Application Number 10/773,618
INFORMATION DISCLOSURE CITATION		Applicant	
IN	I AN APPLICATION	Thomas W. DUBENSKY, Jr. et al.	
(Use several sheets if necessary)		Filing Date February 6, 2004	Group Art Unit 1645
		Mailing Date July 21, 2004	
171.	Sinden, R.R. et al. (November, 1978). "Repair of Cross-Linked DNA and Survival of <i>Escherichia coli</i> Treated with Psoralen and Light: Effects of Mutations Influencing Genetic Recombination and DNA Metabolism," <i>Journal of Bacteriology</i> 136(2):538-547.		
172.	Skoble, J. et al. (August 7, 2000). "Three Regions Within ActA Promote Arp2/3 Complex-Mediated Actin Nucleation and <i>Listeria monocytogenes</i> Motility," <i>The Journal of Cell Biology</i> 150(3):527-538.		
173.	Slansky, J.E. et al. (October, 2000). "Enhanced Antigen-Specific Antitumor Immunity with Altered Peptide Ligands that Stabilize the MHC-Peptide-TCR Complex," <i>Immunity</i> 13:529-538.		
. 174.	Song, F. et al. (1996). "Differential Effects of Viable and Killed Bacteria on IL-12 Expression of Macrophages," <i>The Journal of Immunology</i> 156:2979-2984.		
175.	Starnbach, M.N. et al. (August, 2003). "Anthrax Delivers a Lethal Blow to Host Immunity," <i>Nature Medicine</i> 9(8):996-997.		
176.	Subklewe, M. et al. (August 15, 1999). "Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus," <i>Blood</i> 94(4):1372-1381.		
177.	Sun, A. et al. (November, 1990). "Isolation of <i>Listeria monocytogenes</i> Small-Plaque Mutants Defective for Intracellular Growth and Cell-To-Cell Spread," <i>Infection &amp; Immunity</i> 58(11):3770-3778.		
178.	Tatsumi, T. et al. (August 1, 2003). "Disease Stage Variation in CD4+ and CD8+ T-Cell Reactivity to the Receptor Tyrosine Kinase EphA2 in Patients with Renal Cell Carcinoma," <i>Cancer Res.</i> 63(15):4481-4489.		
179.	Tessman, J.W. et al. (1985). "Photochemistry of the Furan-Side 8-Methoxypsoralen-Thymidine Monoadduct Inside the DNA Helix. Conversion to Diadduct and to Pyrone-Side Monoadduct," <i>Biochemistry</i> 24:1669-1676.		
180.	Thorne, C.B. et al. (1957). "An Agar-Diffusion Method for Titrating <i>Bacillus anthracis</i> Immunizing Antigen and its Application to a Study of Antigen Production," <i>J. Gen. Microbiol.</i> 17:505-516.		
181.	Tilney, L. G. et al. (October, 1989). "Actin Filaments and the Growth, Movement, and Spread of the Intracellular Bacterial Parasite, <i>Listeria monocytogenes</i> ," <i>The Journal of Cell Biology</i> 109:1597-1608.		
182.	Tsang, K.Y. et al. (1995). "Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine," J. Natl. Cancer Inst. 87(13):982-990.		
183.	Tsung, K. et al. (January, 1996). "Gene Expression and Cytopathic Effect of Vaccinia Virus Inactivated by Psoralen and Long-Wave UV Light," <i>Journal of Virology</i> 70(1):165-171.		
184.	Uchida, I. et al. (1997). "Cross-Talk to the Genes for <i>Bacillus Anthracis</i> Capsule Synthesis by <i>atxA</i> , The Gene Encoding the <i>Trans</i> -Activator of Anthrax Toxin Synthesis," <i>Mol. Microbiol.</i> 23(6):1229-1240.		
EXAMINER:		DATE CONSIDERED:	
	tial if citation considered, whether or not the citation considered. Include a copy of this form with n		ine through the citation if not in

Form PTO-1449		Docket Number 282172002800	Application Number 10/773,618
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Thomas W. DUBENSKY, Jr. et al.	
(Use several sheets if necessary)		Filing Date February 6, 2004	Group Art Unit 1645
		Mailing Date July 21, 2004	
185.	Vazquez-Boland, J.A. et al. (July, 2001). "Listeria Pathogenesis and Molecular Virulence Determinants," Chemical Microbiology Reviews 14(3):584-640.		
186.	Wemmer, D. (March, 1998). "Reading DNA," Nature Structural Biology 5(3):169-171.		
187.	Wolfgang, C.D. et al. (August 15, 2000). "TARP: A Nuclear Protein Expressed in Prostate and Breast Cancer Cells Derived from an Alternate Reading Frame of the T Cell Receptor γ Chain Locus," <i>Proc. Natl. Acad. Sci. USA</i> 97(17):9437-9442.		
188.	Wurtz, N.R. et al. (February 14, 2000). "Sequence Specific Alkylation of DNA by Hairpin Pyrrole-Imidazole Polyamide Conjugates," <i>Chemistry &amp; Biology</i> 7:153-161.		
. 189.	Xiong, H. et al. (1998). "Administration of Killed Bacteria Together with Listeriolysin O Induces Protective Immunity Against Listeria monocytogenes in Mice," Immunology 94:14-21.		
. 190.	Zantek, N.D. et al. (September, 1999). "E-Cadherin Regulates the Function of the EphA2 Receptor Tyrosine Kinase," <i>Cell Growth Differ</i> . 10:629-638.		
191.	Zaremba, S. et al. (October 15, 1997). "Identification of an Enhancer Agonist Cytotoxic T Lymphocyte Peptide From Human Carcinoembryonic Antigen," <i>Cancer Res.</i> 57:4570-4577.		
192.	Zhou, Y. et al. (July, 2002). "Current Methods for Loading Dendritic Cells With Tumor Antigen for the Induction of Antitumor Immunity," <i>The Journal of Immunology</i> 25(4):289-303.		
•			

	·
EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.